Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Evaluation of a new, rapid, qualitative, one-step PSA Test for prostate cancer screening: the PSA RapidScreen test

Prostate Cancer and Prostatic Diseases volume 8, pages 219–223 (2005)Cite this article

Abstract

To increase the acceptance rate and reduce the cost of the screening programme for prostate cancer, a new qualitative and one-step test for prostate-specific antigen (PSA), called PSA RapidScreen, has been evaluated. PSA RapidScreen test is a chromatographic lateral flow immunoassay, which generates a positive or negative result for PSA values ⩾or <4 ng/ml, respectively. Capillary blood samples from 188 men were evaluated. Two independent observers interpreted the test at 10, 15, 20 and 25 min. A total of 10 women were tested as controls. Parallel serum samples were simultaneously collected and tested with an ordinary quantitative assay (Elecsys® 2010, Roche). Sensitivity, specificity, accuracy, negative and positive predictive values of the test were 97.6, 90.4, 94, 98 and 89%, respectively. PSA RapidScreen tests on female capillary samples were negative. Reproducibility of the test was 99.5%, while interobserver variation was 5%. Specificity of the test was altered by variations in the reading time. Quantitative assessment of the intensity of the band correlated with the PSA value (r=0.87; t=23.97; P<0.001). PSA RapidScreen is a rapid, simple and reproducible one-step test. The low cost and the speed of the test make it a powerful and convenient tool for prostate cancer screening programmes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. American Cancer Society, Inc. Cancer Facts and Figures 2004. American Cancer Society, Inc: Atlanta, Ga, 2004, pp 1–56.

  2. Crawford ED . Prostate cancer awareness week: September 22–28, 1997. CA Cancer J Clin 1997; 47: 288–296.

    Article  CAS  Google Scholar 

  3. Catalona WJ et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151: 1283–1290.

    Article  Google Scholar 

  4. Stephenson RA, Stanford JL . Population-based prostate cancer trends in the United States: patterns of change in the era of prostate-specific antigen. World J Urol 1997; 15: 331–335.

    Article  CAS  Google Scholar 

  5. Merrill RM, Stephenson RA . Trends in mortality rates inpatients with prostate cancer during the era of prostate specific antigen screening. J Urol 2000; 163: 503–510.

    Article  CAS  Google Scholar 

  6. Bartsch G et al. Prostate cancer mortality after the introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001; 58: 417–424.

    Article  CAS  Google Scholar 

  7. Meyer F, Moore L, Bairati I, Fradet Y . Downward trend in prostate cancer mortality in Quebec and Canada. J Urol 1999; 161: 1189–1191.

    Article  CAS  Google Scholar 

  8. Tarone RE, Chu KC, Brawley OW . Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology 2000; 11: 167–170.

    Article  CAS  Google Scholar 

  9. Optenberg SA, Thompson IM . Economics of screening for carcinoma of the prostate. Urol Clin North Am 1990; 17: 719–737.

    CAS  PubMed  Google Scholar 

  10. Littrup PJ et al. Cost-effective prostate cancer detection. Cancer 1994; 74: 3146–3158.

    Article  CAS  Google Scholar 

  11. Potter SR et al. Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer. Urology 2001; 57: 1100–1104.

    Article  CAS  Google Scholar 

  12. Martin E et al. Final results of a screening campaign for prostate cancer. Eur Urol 1999; 35: 26–31.

    Article  CAS  Google Scholar 

  13. Gustafsson O et al. Diagnostic methods in the detection of prostate cancer. A study of a randomly selected population of 2,400 men. J Urol 1992; 148: 1827–1831.

    Article  CAS  Google Scholar 

  14. Reissigl A et al. Prostate carcinoma screening in the county of Tyrol, Austria: experience and results. Cancer 1997; 80: 1818–1829.

    Article  CAS  Google Scholar 

  15. Berg W, Linder C, Eschholz G, Schubert J . Pilot study of the practical relevance of a one-step test for prostate-specific antigen in capillary blood to improve the acceptance rate in the early detection program of prostate carcinoma. Int Urol Nephrol 2001; 32: 381–388.

    Article  CAS  Google Scholar 

  16. Dok An C, Yoshiki T, Lee G, Okada Y . Evaluation of a rapid qualitative prostate specific antigen assay, the One Step PSA™ test. Cancer Lett 2001; 162: 135–139.

    Article  CAS  Google Scholar 

  17. Jung K et al. Rapid detection of elevated prostate-specific antigen levels in blood: performance of various membrane strip tests compared. Urology 1999; 53: 155–160.

    Article  CAS  Google Scholar 

  18. Madersbacher S, Mian C, Maier U, Simak R . Validation of a 10-minute dipstick test for serum prostate-specific antigen. Eur Urol 1996; 30: 446–450.

    Article  CAS  Google Scholar 

  19. Carvalhal GF et al. Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng/ml or less. J Urol 1999; 161: 835–839.

    Article  CAS  Google Scholar 

  20. Roehl KA, Antenor JA, Catalona WJ . Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6–4.0 ng/ml range. J Urol 2002; 168: 922–925.

    Article  Google Scholar 

Download references

Acknowledgements

This study was supported by the Italian Tumour League, Provincial Section of Cosenza, Italy. We are grateful to all the staff and in particular to Avv. Franco Martire and Prof. Luigi Pugliese, President and Vice-President of the Provincial Section of Cosenza respectively, for their kind and essential support.

Author information

Authors and Affiliations

  1. Department of Urology, Policlinico Tor Vergata, University of Rome ‘Tor Vergata’, Rome, Italy

    R Miano, S Germani, P Bove, S Sansalone & F Micali

  2. Italian Tumour League, Provincial Section of Cosenza, Italy

    G O Mele & P F Pugliese

Authors
  1. R Miano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G O Mele
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Germani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P Bove
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Sansalone
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P F Pugliese
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F Micali
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Miano.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miano, R., Mele, G., Germani, S. et al. Evaluation of a new, rapid, qualitative, one-step PSA Test for prostate cancer screening: the PSA RapidScreen test. Prostate Cancer Prostatic Dis 8, 219–223 (2005). https://doi.org/10.1038/sj.pcan.4500802

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500802

Keywords

This article is cited by

Search

Advanced search

Quick links